https://www.marketwatch.com/story/mercks-stock-rallies-toward-a-record-after-fda-oks-arterial-hypertension-drug-d2259422?mod=mw_rss_topstories
Merck’s stock rallied into record territory Wednesday, after the drug giant’s treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administration…

Merck’s stock rallies toward a record after FDA OKs arterial-hypertension drug
More from BusinessMore posts in Business »
- IMF chief visits Argentina as 2027 debt hurdle looms
- China calls on US to stop AI sanctions
- Indonesia faces test of central bank independence after governor’s shock exit
- German firms delay investments as energy costs climb, lobby group says
- Poland may act on fuel prices if volatility persists, PM says
- How Will Bitcoin, Ethereum and XRP React if CLARITY Act Passes or Fails?
- Artificial Superintelligence Alliance (FET) Price Prediction 2026, 2027-2030
- Bitcoin Price Today: Weak Spot Demand Keeps BTC Under Pressure
- AAVE Price Could Be One Breakout Away From a Massive Rally
- Pump.fun (PUMP) Price Prediction 2026,2027-2030: Will PUMP Lead Solana’s DeFi Boom?
More from UncategorizedMore posts in Uncategorized »
- How Public Equity Can Promote a Revived American Democracy
- IMF chief visits Argentina as 2027 debt hurdle looms
- China calls on US to stop AI sanctions
- Indonesia faces test of central bank independence after governor’s shock exit
- German firms delay investments as energy costs climb, lobby group says
- Poland may act on fuel prices if volatility persists, PM says
- How Will Bitcoin, Ethereum and XRP React if CLARITY Act Passes or Fails?
- Artificial Superintelligence Alliance (FET) Price Prediction 2026, 2027-2030
- Bitcoin Price Today: Weak Spot Demand Keeps BTC Under Pressure
- AAVE Price Could Be One Breakout Away From a Massive Rally





